Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer

By Ronquist Gunnar   Frithz Goran   Wang Yu-Hui   Lindeborg Torsten  

Scandinavian Journal of Urology and Nephrology, Vol. 43, Iss. 1, 2009-02 ,pp. : 32-36

Informa Healthcare

Access to resources Recommend Favorite

Management of patients with rising prostate-specific antigen after radical prostatectomy

By Laufer M.   Pound C.R.   Carducci M.A.   Eisenberger M.A.  

Urology, Vol. 55, Iss. 3, 2000-03 ,pp. : 309-315

Elsevier

Access to resources Recommend Favorite

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

By Dillioglugil O.   Leibman B.D.   Kattan M.W.   Seale-Hawkins C.   Wheeler T.M.   Scardino P.T.  

Urology, Vol. 50, Iss. 1, 1997-07 ,pp. : 93-99

Elsevier

Access to resources Recommend Favorite

Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era

By Ung J.O.   Richie J.P.   Chen M.-H.   Renshaw A.A.   D'Amico A.V.  

Urology, Vol. 60, Iss. 3, 2002-09 ,pp. : 458-463

Elsevier

Access to resources Recommend Favorite

Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer

By Pruthi R.S.   Johnstone I.   Tu I.-P.   Stamey T.A.  

Urology, Vol. 49, Iss. 5, 1997-05 ,pp. : 737-742

Elsevier

Access to resources Recommend Favorite